U.S. approves GM potato with lower cancer risk

Reading Time: < 1 minute

Published: November 13, 2014

WASHINGTON, D.C. (Reuters) — The United States Department of Agriculture has approved the first genetically modified potato for commercial planting in the country, a move likely to draw the ire of groups opposed to artificial manipulation of foods.

The so-called Innate potato, developed by the J.R. Simplot Company, is engineered to contain less of a suspected human carcinogen that occurs when a conventional potato is fried, and is also less prone to bruising during transport.

Idaho-based Simplot is a major supplier of frozen French fries to fast food giant McDonald’s Corp.

Read Also

Port of Churchill. Given by the Port for our use.

Saskatchewan, Manitoba sign Arctic Gateway deal

Saskatchewan, Manitoba and Arctic Gateway Group have signed an MOU to strengthen trade through the Port of Churchill.

The Nov. 7 announcement came from the USDA’s Animal and Plant Health Inspection Service (APHIS). Simplot applied to APHIS for approval of the Innate potato in 2013. The submission was also reviewed by the Environmental Protection Agency and the Food and Drug Administration.

Field trials of the potato were conducted from 2009 through 2011 in eight states: Florida, Indiana, Idaho, Michigan, Nebraska, North Dakota, Washington and Wisconsin.

Genetic modification is more common in crops such as corn and soybeans. More than 90 percent of U.S. soybeans and about 89 percent of U.S. corn are genetically modified for herbicide tolerance or other traits.

But the potential adoption of genetic modification has been more controversial in food crops such as wheat, where no GM varieties are approved in the United States, and for fruits and vegetables.

APHIS said it received hundreds of submissions from individuals or groups about Simplot’s potato during a public comment period.

Among those opposing the potato were individuals and groups broadly opposed to the development of GM crops in general, as well as to the regulatory framework surrounding genetic modification, APHIS said.

The potential for human benefits — a lower cancer risk for consumers — was among the positives cited in public comments.

explore

Stories from our other publications